KRAS and cancer: This observation has important clinical implications as it suggests only KRAS-mutant patients with an inflamed TME would benefit from the combination of KRAS inhibitors and ICB and calls into question whether such a combination would be effective in ICB nonresponsive cancer types such as colorectal cancer and PDAC.